Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CervoMed Inc. (NASDAQ: CRVO) SEC filings, offering a detailed view of how the clinical-stage biotechnology company reports its operations, financial condition, and development plans for neflamapimod and related programs. As a NASDAQ Capital Market issuer, CervoMed files current reports on Form 8-K, annual reports on Form 10-K, and other documents that outline its progress in dementia with Lewy bodies (DLB) and other age-related brain disorders.
In recent Form 8-K filings, CervoMed has furnished press releases covering quarterly financial results, new clinical data from the Phase 2b RewinD-LB trial, and written feedback from the U.S. Food and Drug Administration on the design of its planned Phase 3 trial in DLB. These filings describe how the company plans to use endpoints such as change in Clinical Dementia Rating – Sum of Boxes (CDR-SB), enrichment strategies based on plasma ptau181, and biomarker assessments like glial fibrillary acidic protein (GFAP) to support a potential New Drug Application for neflamapimod.
Other 8-Ks document corporate governance events, including the appointment of new directors and executive officers, adoption of equity incentive plans, and stock option grants. Filings relating to the annual meeting of stockholders detail voting outcomes on director elections, auditor ratification, advisory votes on executive compensation, and approval of equity plans. Together, these documents provide a structured record of CervoMed’s governance, capital structure, and incentive arrangements.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new 8-Ks, 10-Qs, and 10-Ks as they are filed, while AI-generated highlights can point to important disclosures on clinical trial results, regulatory milestones, grant funding, and risk factors. Investors can also use the filings page to monitor how CervoMed describes its lead program, neflamapimod, and its broader strategy in age-related brain disorders over time.
AWM Investment Company, Inc. amended a Schedule 13G to report beneficial ownership of 405,165 shares (or share-equivalents) of CervoMed Inc., representing 4.2% of the class. The filing explains AWM holds sole voting and dispositive power over those positions through its advisory role to three funds, with a detailed split of 235,126, 68,748 and 101,291 warrants held by the named funds. The amendment was signed on 04/07/2026.
CervoMed Inc. is providing a detailed update on its lead drug candidate neflamapimod for dementia with Lewy bodies (DLB). The company is presenting new MRI analyses from the 159-patient Phase 2b RewinD-LB trial, global regulatory discussions, and a finalized Phase 3 trial design at the 2026 Lewy Body Dementia Association Annual Meeting.
Neflamapimod’s MRI data suggest a potential positive effect on basal forebrain atrophy and functional connectivity, and blood biomarker data (plasma GFAP) appear responsive to treatment. CervoMed plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding, while also highlighting prior Phase 2a and 2b results showing clinical and biomarker signals.
CervoMed Inc. filed a current report describing an investor presentation that has been made available on its website under the “Investors – Events and Presentations” section. Company representatives may use this material, with possible non‑material modifications, in meetings and conferences with investors and analysts.
The company emphasizes that the presentation is summary information meant to be read together with its other SEC filings and public announcements. The information in this report is being furnished under Item 7.01 and is not deemed “filed” for purposes of the Securities Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
CervoMed reported new analyses from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). Patients with lower plasma pTau181 levels, indicating fewer with Alzheimer’s co-pathology, showed greater clinical benefit on key measures such as CDR-SB and ADCS-CGIC.
The company will use a plasma pTau181 enrichment cutoff of <21 pg/mL in its planned global Phase 3 DLB trial, aiming to enroll mainly “pure” DLB patients. PK/PD analyses focused on this population support the planned 50mg TID dosing regimen. CervoMed plans to start Phase 3 in the second half of 2026, subject to available funding.
CervoMed Inc. reported fourth quarter and full year 2025 results and highlighted progress for its lead drug neflamapimod in dementia with Lewy bodies (DLB) and other brain disorders. The company reported positive Phase 2b RewinD-LB data and reached alignment with U.S. and global regulators on a planned Phase 3 trial design, formulation, dose, and dosing regimen in DLB.
As of December 31, 2025, CervoMed had approximately $20.9 million in cash, cash equivalents and marketable securities, down from $38.9 million a year earlier, and believes this will fund operations for approximately six months from the date of the release. Grant revenue declined to about $4.0 million in 2025 from $9.7 million in 2024 due to completion of the RewinD-LB trial phases.
Research and development expenses rose to roughly $21.8 million from $18.8 million, driven by manufacturing improvements, batch-related work from RewinD-LB, and new trials in ischemic stroke recovery and primary progressive aphasia. General and administrative expenses increased to about $10.5 million from $9.2 million, and net loss widened to approximately $27.0 million from $16.2 million.
CervoMed Inc. is a clinical-stage biotech focused on age-related brain disorders, led by its oral p38α inhibitor neflamapimod. The drug is being developed primarily for dementia with Lewy bodies (DLB) without Alzheimer’s co-pathology, where there are currently no approved disease-specific treatments.
The company reports positive Phase 2a and 2b signals in DLB and alignment with the FDA on a single global Phase 3 trial using CDR-SB as the primary endpoint over 32 weeks in about 300 patients, subject to funding. Neflamapimod is also in Phase 2a studies for nonfluent primary progressive aphasia and recovery after ischemic stroke, and selected for evaluation in the EXPERTS-ALS platform trial.
CervoMed highlights manufacturing improvements to stabilize neflamapimod’s crystal form after earlier batch-related exposure issues, extensive nonclinical and human safety data with liver-enzyme monitoring, Fast Track designation in DLB, and Orphan Drug Designation in frontotemporal dementia. As of March 11, 2026, 9,258,719 shares of common stock were outstanding.
CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating a new, stable crystal form of its lead drug candidate neflamapimod and used the results to select the dose for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company plans to use a 50mg three-times-daily regimen of the stable crystal form in Phase 3 to match the plasma drug levels associated with the clinically active batch from its prior RewinD-LB Phase 2b trial. Management highlights that a controlled manufacturing process now consistently produces the stable form, aiming to avoid past variability seen with less stable polymorphs.
CervoMed reiterates neflamapimod’s potential in DLB and other degenerative brain disorders based on earlier Phase 2 data and states it plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been selected for inclusion in the UK-based EXPERTS-ALS platform, which rapidly tests potential treatments for amyotrophic lateral sclerosis (ALS) using biomarker-based trials. This will be the first clinical evaluation of neflamapimod in ALS.
Neflamapimod, an oral small molecule that crosses the blood–brain barrier and selectively inhibits p38 MAP kinase, will initially be studied in approximately 35 ALS participants for 18–24 weeks, with possible expansion to up to 80 patients. The trial will measure changes in blood neurofilament light chain, a marker linked to neuroaxonal damage and ALS progression, and include clinical and survival endpoints.
Trial costs in EXPERTS-ALS are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, while CervoMed continues to focus on dementia with Lewy bodies (DLB) and plans a global Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options. On February 11, 2026, he was awarded options to acquire 30,000 shares of CervoMed common stock at an exercise price of $4.8 per share.
The award vests in 36 roughly equal monthly installments, with vesting starting on February 28, 2026 and continuing on the last calendar day of each month over three years. All 30,000 derivative securities are reported as directly owned following this grant.
CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.
The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.